Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (141-150 of 201) with videos related to

Pageof 21
Sort By:
The Journal of Molecular Diagnostics : JMD|May 22, 2024
Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical CareAileen Y Alontaga, Pedro Cano, Hilal Ozakinci, et al.
Cancer Chemotherapy and Pharmacology|March 25, 2011
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsGeorge R Simon, Robert L Ilaria, Mika A Sovak, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2023
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutationsAndreas N Saltos, Ben C Creelan, Tawee Tanvetyanon, et al.
Molecular Cancer Therapeutics|May 20, 2016
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung CancerAnkita Jhuraney, Nicholas T Woods, Gabriela Wright, et al.
Plos One|January 21, 2016
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerTakeshi Yoshida, Lanxi Song, Yun Bai, et al.
Journal of the National Cancer Institute|December 4, 2014
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancerChunxia Cao, Ruli Gao, Min Zhang, et al.
Cell Chemical Biology|July 2, 2019
Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual TargetsNatalia J Sumi, Claudia Ctortecka, Qianqian Hu, et al.
Cancer Research|October 30, 2025
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C InhibitorsYaakov E Stern, Pompom Ghosh, John Peroza, et al.
American Journal of Hematology|March 5, 2024
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasmsGarima Pandey, Lucia Mazzacurati, Tegan M Rowsell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2016
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung AdenocarcinomaHong Zheng, Weipeng Zhao, Cihui Yan, et al.
Pageof 21

Showing results (141-150 of 201) with videos related to

Sort By:
Pageof 21
The Journal of Molecular Diagnostics : JMD|May 22, 2024
Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical CareAileen Y Alontaga, Pedro Cano, Hilal Ozakinci, et al.
Cancer Chemotherapy and Pharmacology|March 25, 2011
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsGeorge R Simon, Robert L Ilaria, Mika A Sovak, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2023
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutationsAndreas N Saltos, Ben C Creelan, Tawee Tanvetyanon, et al.
Molecular Cancer Therapeutics|May 20, 2016
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung CancerAnkita Jhuraney, Nicholas T Woods, Gabriela Wright, et al.
Plos One|January 21, 2016
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerTakeshi Yoshida, Lanxi Song, Yun Bai, et al.
Journal of the National Cancer Institute|December 4, 2014
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancerChunxia Cao, Ruli Gao, Min Zhang, et al.
Cell Chemical Biology|July 2, 2019
Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual TargetsNatalia J Sumi, Claudia Ctortecka, Qianqian Hu, et al.
Cancer Research|October 30, 2025
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C InhibitorsYaakov E Stern, Pompom Ghosh, John Peroza, et al.
American Journal of Hematology|March 5, 2024
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasmsGarima Pandey, Lucia Mazzacurati, Tegan M Rowsell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2016
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung AdenocarcinomaHong Zheng, Weipeng Zhao, Cihui Yan, et al.
Pageof 21